Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.

Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression

Open access

Abstract

Blockade of the checkpoint inhibitor programmed death 1 (PD1) has demonstrated remarkable success in the clinic for the treatment of cancer; however, a majority of tumors are resistant to anti-PD1 monotherapy. Numerous ongoing clinical combination therapy studies will likely reveal additional therapeutics that complement anti-PD1 blockade. Recent studies found that immunogenic cell death (ICD) improves T cell responses against different tumors, thus indicating that ICD may further augment antitumor immunity elicited by anti-PD1. Here, we observed antitumor activity following combinatorial therapy with anti-PD1 Ab and the cyclin-dependent kinase inhibitor dinaciclib in immunocompetent mouse tumor models. Dinaciclib induced a type I IFN gene signature within the tumor, leading us to hypothesize that dinaciclib potentiates the effects of anti-PD1 by eliciting ICD. Indeed, tumor cells treated with dinaciclib showed the hallmarks of ICD including surface calreticulin expression and release of high mobility group box 1 (HMGB1) and ATP. Mice treated with both anti-PD1 and dinaciclib showed increased T cell infiltration and DC activation within the tumor, indicating that this combination improves the overall quality of the immune response generated. These findings identify a potential mechanism for the observed benefit of combining dinaciclib and anti-PD1, in which dinaciclib induces ICD, thereby converting the tumor cell into an endogenous vaccine and boosting the effects of anti-PD1.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci94586

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 88 references

Cited by

See all 218

Metadata

Authors
Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., & Chackerian, A.
Affiliations
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
Chackerian, Alissa
Venue
Journal of Clinical Investigation
Published
2018-01-16
Volume
128
Issue
2
Pages
644-654
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2783507731
Cited by
216
References
88
Citations by year
2026: 11 · 2025: 25 · 2024: 37 · 2023: 45 · 2022: 29 · 2021: 22 · 2020: 32 · 2019: 11 · 2018: 4
FWCI
6.48
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
dinaciclib, immunogenic cell death, anti-PD-1 therapy, combination cancer immunotherapy, cyclin-dependent kinase inhibitors, type I interferon signature, calreticulin, HMGB1, ATP release, T cell infiltration, tumor immunogenicity, cancer vaccines
MeSH terms
Adenocarcinoma, Adenosine Triphosphate, Animals, Antibodies, Monoclonal, Cyclic N-Oxides, Dendritic Cells, Drug Synergism, Female, Immune System, Immunotherapy, Indolizines, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasm Transplantation, Phagocytosis, Pyridinium Compounds, Cytokines, Cell Death, Apoptosis, Mice, Knockout, CD8-Positive T-Lymphocytes, Bridged Bicyclo Compounds, Heterocyclic, HMGB1 Protein, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression. https://app.cochat.ai/papers/10.1172/jci94586
The paper
Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., & Chackerian, A. (2018). Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression. Journal of Clinical Investigation. https://doi.org/10.1172/jci94586

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.